Program Schedule

Broadly Active Antiviral: Brincidofovir

Session: Symposium: New Therapeutic Approaches for DNA Viral Infections
Friday, October 10, 2014: 11:00 AM
Room: The Pennsylvania Convention Center: 120-ABC
Roy F. Chemaly, MD, MPH, FIDSA, FACP, Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX

Dr Roy Chemaly is a Professor of Medicine in the Department of Infectious Diseases, Infection Control & Employee Health at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Chemaly completed his training in infectious diseases and medical microbiology at the Cleveland Clinic Foundation in Ohio. He is board-certified in internal medicine/infectious diseases and medical microbiology. During his fellowship, Dr. Chemaly completed a master’s degree in public health from Northeastern Ohio Universities in Rootstown, Ohio. He is also certified in health care delivery research, having successfully completed the Advanced Training Program in Health Care Delivery Research and Improvement provided by Intermountain Health Care Institute in Salt Lake City, Utah. In addition to Dr. Chemaly’s clinical research work in virology and multi-drug resistant organisms, he is the director of the Infection Control and the Antimicrobial Stewardship programs at MD Anderson Cancer Center. He also serves on many institutional committees, including the Infection Control Committee as the chair, Institutional Review Board as a vice chair, the Executive Committee of the Medical Staff, and the Patient Safety Committee. Dr. Chemaly also heads the Viral Protection Ad Hoc Infection Control Subcommittee as well as the Clinical Virology Research Program in the Department of Infectious Diseases as Director. Dr. Chemaly’s work has been reported in numerous peer-reviewed journals and is a reviewer for many high-impact journals. He was elected as a fellow of the American College of Physicians, the Infectious Diseases Society of America. He was recently appointed as the chair of the Transplant Infectious Diseases Special Interest Group of the American Society of Bone Marrow Transplantation.

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, All Rights Reserved.

Follow IDWeek